G01N 2333/96433
Serine endopeptidases
Official title: Serine endopeptidases (3.4.21)
G01N2333/96433 (Serine endopeptidases) appears on 603 US grants and 832 published applications in this corpus.
Search patents in G01N- Granted patents
- 603
- Published applications
- 832
- Assignees
- 531
- Inventors
- 1,714
- Latest grant
- 29 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1977 | 1 | 0 |
| 1978 | 0 | 0 |
| 1979 | 2 | 0 |
| 1980 | 2 | 0 |
| 1981 | 3 | 0 |
| 1982 | 3 | 0 |
| 1983 | 2 | 0 |
| 1984 | 2 | 0 |
| 1985 | 0 | 0 |
| 1986 | 2 | 0 |
| 1987 | 2 | 0 |
| 1988 | 3 | 0 |
| 1989 | 4 | 0 |
| 1990 | 4 | 0 |
| 1991 | 5 | 0 |
| 1992 | 3 | 0 |
| 1993 | 6 | 0 |
| 1994 | 8 | 0 |
| 1995 | 11 | 0 |
| 1996 | 12 | 0 |
| 1997 | 25 | 0 |
| 1998 | 43 | 0 |
| 1999 | 17 | 0 |
| 2000 | 24 | 0 |
| 2001 | 16 | 2 |
| 2002 | 15 | 16 |
| 2003 | 8 | 36 |
| 2004 | 9 | 21 |
| 2005 | 9 | 19 |
| 2006 | 12 | 27 |
| 2007 | 6 | 24 |
| 2008 | 4 | 16 |
| 2009 | 7 | 22 |
| 2010 | 14 | 34 |
| 2011 | 17 | 26 |
| 2012 | 16 | 36 |
| 2013 | 14 | 38 |
| 2014 | 21 | 33 |
| 2015 | 25 | 62 |
| 2016 | 14 | 70 |
| 2017 | 25 | 40 |
| 2018 | 25 | 33 |
| 2019 | 26 | 37 |
| 2020 | 22 | 38 |
| 2021 | 27 | 31 |
| 2022 | 22 | 39 |
| 2023 | 16 | 30 |
| 2024 | 14 | 32 |
| 2025 | 21 | 36 |
| 2026 | 14 | 34 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Methods for detection of pathogenic antiphospholipid antibodies and for identification of inhibitors29 Sep 2026US 12,748,111 B2The Scripps Research Institute
- Kits22 Sep 2026US 12,742,779 B1Takeda Pharmaceutical Company Limited
- Heparin-insensitive assay for factor XIa25 Aug 2026US 12,716,084 B2Takeda Pharmaceutical Company Limited
- Monoclonal antibody against human activated protein C and preparation and use thereof18 Aug 2026US 12,708,662 B2Oklahoma Medical Research Foundation
- Use of caseinolytic protease P function as a biomarker of drug response to imipridone-like agents28 Jul 2026US 12,692,267 B2Madera Therapeutics, LLC
- Tau assay8 Oct 2026US 2026/0309720 A1
- Oligonucleotide Modulators Activating Factor VII Expression and Use Thereof in Treatment of Hemophilia10 Sep 2026US 2026/0265739 A1
- Method for potency determination of haina polysaccharide (hps)10 Sep 2026US 2026/0266853 A1Harbin Hongdoushan Bio-Pharm Co., Ltd.
- Humoral Immune Activators for the Treatment of Humoral Immunosuppressed Pathologies, Cancer and Infectious Disease and Humoral Immune Suppressors for the Treatment of Inflammatory Diseases3 Sep 2026US 2026/0256811 A1Navrogen, Inc.
- Methods and devices for detection of coagulation impairment3 Sep 2026US 2026/0259231 A1Coagulo Medical Technologies, Inc.
Most cited
By later US patents
- Methods for identifying nucleic acid ligands856US 5,270,163 AUniversity Research Corporation · 1993
- Nucleic acid ligands561US 5,475,096 AUniversity Research Corporation · 1995
- Systematic evolution of ligands by exponential enrichment: Solution SELEX337US 5,567,588 AUniversity Research Corporation · 1996
- Systematic evolution of ligands by exponential enrichment: chimeric selex281US 5,637,459 ANeXstar Pharmaceuticals, Inc. · 1997
- High-affinity nucleic acid ligands that discriminate between theophylline and caffeine277US 5,580,737 ANeXstar Pharmaceuticals, Inc. · 1996